Annals of Hematology

, 84:3

Decitabine: a historical review of the development of an epigenetic drug

Original Article

DOI: 10.1007/s00277-005-0008-x

Cite this article as:
de Vos, D. & van Overveld, W. Ann Hematol (2005) 84(Suppl 1): 3. doi:10.1007/s00277-005-0008-x


The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem cell transplant, sickle cell anemia and thalassemia looks promising. The epigenetic dose seems lower than the cytotoxic dose. Whereas most drugs have matured after 40 years, decitabine is only at the beginning of a new development phase in epigenesis.


Hypomethylation MDS AML CML stem cell sickle cell 

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Pharmachemie BVHaarlemThe Netherlands

Personalised recommendations